clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Infant, Premature, Diseases D007235 7 associated lipids
Parkinson Disease D010300 53 associated lipids
Monoclonal Gammopathy of Undetermined Significance D008998 2 associated lipids
Influenza, Human D007251 11 associated lipids
Lymphadenitis D008199 8 associated lipids
Drug Eruptions D003875 30 associated lipids
Skin Diseases, Infectious D012874 7 associated lipids
Eye Infections, Bacterial D015818 3 associated lipids
Synovitis D013585 15 associated lipids
Peptic Ulcer Perforation D010439 3 associated lipids
Carcinoma, Lewis Lung D018827 22 associated lipids
Renal Insufficiency D051437 8 associated lipids
Ventricular Dysfunction, Left D018487 33 associated lipids
Genetic Predisposition to Disease D020022 24 associated lipids
Plaque, Atherosclerotic D058226 7 associated lipids
Insulin Resistance D007333 99 associated lipids
Liver Failure, Acute D017114 11 associated lipids
Periodontal Attachment Loss D017622 7 associated lipids
Bacteremia D016470 9 associated lipids
Hemophilia A D006467 10 associated lipids
Encephalitis D004660 15 associated lipids
Barrett Esophagus D001471 3 associated lipids
Rhabdomyolysis D012206 9 associated lipids
Gingival Overgrowth D019214 7 associated lipids
Meningitis, Bacterial D016920 6 associated lipids
Actinomycetales Infections D000193 4 associated lipids
Pneumonia, Bacterial D018410 16 associated lipids
Rosacea D012393 13 associated lipids
Psychoses, Substance-Induced D011605 7 associated lipids
Neurotoxicity Syndromes D020258 34 associated lipids
Abortion, Spontaneous D000022 12 associated lipids
Esophagitis, Peptic D004942 4 associated lipids
Helicobacter Infections D016481 21 associated lipids
Dermatitis, Phototoxic D017484 4 associated lipids
Keratoconjunctivitis D007637 3 associated lipids
Gastroesophageal Reflux D005764 10 associated lipids
Community-Acquired Infections D017714 8 associated lipids
Mycobacterium avium-intracellulare Infection D015270 4 associated lipids
Hand Dermatoses D006229 5 associated lipids
Gastritis, Atrophic D005757 4 associated lipids
Ergotism D004881 4 associated lipids
Ecchymosis D004438 3 associated lipids
AIDS-Related Opportunistic Infections D017088 9 associated lipids
Psychophysiologic Disorders D011602 3 associated lipids
Dyspepsia D004415 5 associated lipids
Skin Diseases, Bacterial D017192 8 associated lipids
Giardiasis D005873 3 associated lipids
Common Variable Immunodeficiency D017074 4 associated lipids
Purpura, Thrombocytopenic, Idiopathic D016553 4 associated lipids
Peptic Ulcer Hemorrhage D010438 4 associated lipids
Eye Injuries, Penetrating D015807 2 associated lipids
Prurigo D011536 4 associated lipids
Chlamydia Infections D002690 7 associated lipids
Legionnaires' Disease D007877 4 associated lipids
Whooping Cough D014917 6 associated lipids
Urethritis D014526 9 associated lipids
Boutonneuse Fever D001907 5 associated lipids
Fistula D005402 8 associated lipids
Dermatitis, Exfoliative D003873 10 associated lipids
Confusion D003221 4 associated lipids
Uveitis, Anterior D014606 11 associated lipids
Chromoblastomycosis D002862 2 associated lipids
Soft Tissue Injuries D017695 2 associated lipids
Lymphoma, T-Cell, Cutaneous D016410 4 associated lipids
Bronchiectasis D001987 7 associated lipids
Bronchiolitis Obliterans D001989 8 associated lipids
Parotitis D010309 4 associated lipids
Iris Diseases D007499 2 associated lipids
Exanthema D005076 11 associated lipids
Bronchiolitis D001988 6 associated lipids
Conjunctival Neoplasms D003230 3 associated lipids
Chlamydophila Infections D023521 4 associated lipids
Ureteral Diseases D014515 3 associated lipids
IgA Deficiency D017098 2 associated lipids
Cryptogenic Organizing Pneumonia D018549 3 associated lipids
Ureaplasma Infections D016869 5 associated lipids
Erythema Nodosum D004893 5 associated lipids
Soft Tissue Infections D018461 2 associated lipids
alpha 1-Antitrypsin Deficiency D019896 3 associated lipids
Pleuropneumonia D011001 3 associated lipids
Cytomegalovirus Retinitis D017726 2 associated lipids
Still's Disease, Adult-Onset D016706 2 associated lipids
Leprosy, Borderline D015439 3 associated lipids
Discitis D015299 2 associated lipids
Cardiovascular Abnormalities D018376 2 associated lipids
Pneumonia, Mycoplasma D011019 6 associated lipids
Desulfovibrionaceae Infections D045824 5 associated lipids
Periodontal Abscess D010508 2 associated lipids
Sexually Transmitted Diseases, Bacterial D015231 5 associated lipids
Conjunctivitis, Bacterial D003234 3 associated lipids
Psittacosis D009956 4 associated lipids
Angiomatosis, Bacillary D016917 2 associated lipids
Mycetoma D008271 4 associated lipids
Diphtheria D004165 2 associated lipids
Empyema D004653 3 associated lipids
Rickettsia Infections D012282 5 associated lipids
Sporotrichosis D013174 3 associated lipids
Pleural Diseases D010995 4 associated lipids
Bartonella Infections D001474 3 associated lipids
Lymphangitis D008205 4 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Wheeldon TU et al. Helicobacter pylori eradication and peptic ulcer healing: the impact of deleting the proton pump inhibitor and using a once-daily treatment. 2003 Aliment. Pharmacol. Ther. pmid:12848630
Dalla Libera M et al. High effectiveness and safety of one-week antibiotic regimen in Helicobacter pylori eradication. 1996 Aliment. Pharmacol. Ther. pmid:8730251
Labenz J et al. One-week triple therapy with omeprazole, amoxycillin and either clarithromycin or metronidazole for cure of Helicobacter pylori infection. 1996 Aliment. Pharmacol. Ther. pmid:8730252
Huang J et al. Randomised controlled trial: sequential vs. standard triple therapy for Helicobacter pylori infection in Chinese children-a multicentre, open-labelled study. 2013 Aliment. Pharmacol. Ther. pmid:24117692
Chacko Y and Holtmann GJ Helicobacter pylori eradication and weight gain: has it opened a Pandora's box? 2011 Aliment. Pharmacol. Ther. pmid:21679208
Nseir W et al. Randomised clinical trial: simvastatin as adjuvant therapy improves significantly the Helicobacter pylori eradication rate--a placebo-controlled study. 2012 Aliment. Pharmacol. Ther. pmid:22646167
Zullo A et al. High rate of Helicobacter pylori eradication with sequential therapy in elderly patients with peptic ulcer: a prospective controlled study. 2005 Aliment. Pharmacol. Ther. pmid:15948808
Gisbert JP and Calvet X Review article: rifabutin in the treatment of refractory Helicobacter pylori infection. 2012 Aliment. Pharmacol. Ther. pmid:22129228
Bühling A et al. Influence of anti-Helicobacter triple-therapy with metronidazole, omeprazole and clarithromycin on intestinal microflora. 2001 Aliment. Pharmacol. Ther. pmid:11552917
Hokari K et al. Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism. 2001 Aliment. Pharmacol. Ther. pmid:11552922
Dani R et al. Omeprazole, clarithromycin and furazolidone for the eradication of Helicobacter pylori in patients with duodenal ulcer. 1999 Aliment. Pharmacol. Ther. pmid:10594400
Kamberoglou D et al. Comparison of 1-week vs. 2- or 4-week therapy regimens with ranitidine bismuth citrate plus two antibiotics for Helicobacter pylori eradication. 2001 Aliment. Pharmacol. Ther. pmid:11552924
Harris A The importance of clarithromycin dose in the management of H. pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole. 1999 Aliment. Pharmacol. Ther. pmid:10594406
Harb AH et al. Systematic review and meta-analysis: full- vs. half-dose anti-microbials in clarithromycin-based regimens for Helicobacter pylori eradication. 2015 Aliment. Pharmacol. Ther. pmid:26011564
al-Assi MT et al. Clarithromycin-amoxycillin therapy for Helicobacter pylori infection. 1994 Aliment. Pharmacol. Ther. pmid:7986970
Neri M et al. Omeprazole, bismuth and clarithromycin in the sequential treatment of Helicobacter pylori infection. 1994 Aliment. Pharmacol. Ther. pmid:7986974
Lai KC et al. Effect of treatment of Helicobacter pylori on the prevention of gastroduodenal ulcers in patients receiving long-term NSAIDs: a double-blind, placebo-controlled trial. 2003 Aliment. Pharmacol. Ther. pmid:12641502
Zullo A et al. High eradication rates of Helicobacter pylori with a new sequential treatment. 2003 Aliment. Pharmacol. Ther. pmid:12641522
Spinzi GC et al. Seven-day triple therapy with ranitidine bismuth citrate or omeprazole and two antibiotics for eradication of Helicobacter pylori in duodenal ulcer: a multicentre, randomized, single-blind study. 2000 Aliment. Pharmacol. Ther. pmid:10735926
Graham DY et al. Furazolidone combination therapies for Helicobacter pylori infection in the United States. 2000 Aliment. Pharmacol. Ther. pmid:10651662
Wong BC et al. Comparison of lansoprazole-based triple and dual therapy for treatment of Helicobacter pylori-related duodenal ulcer: an Asian multicentre double-blind randomized placebo controlled study. 2000 Aliment. Pharmacol. Ther. pmid:10651663
Fock KM et al. Triple therapy in the eradication of Helicobacter pylori in patients with duodenal ulcer disease: results of a multicentre study in South-East Asia. South-East Asia Multicenter Study Group. 2000 Aliment. Pharmacol. Ther. pmid:10651664
Harris AW et al. Eradication of Helicobacter pylori with lansoprazole and clarithromycin. 1995 Aliment. Pharmacol. Ther. pmid:7605863
Katelaris PH et al. A randomized prospective comparison of clarithromycin versus amoxycillin in combination with omeprazole for eradication of Helicobacter pylori. 1995 Aliment. Pharmacol. Ther. pmid:7605864
Yousfi MM et al. Metronidazole, omeprazole and clarithromycin: an effective combination therapy for Helicobacter pylori infection. 1995 Aliment. Pharmacol. Ther. pmid:7605865
Sheu BS et al. Impact of intravenous omeprazole on Helicobacter pylori eradication by triple therapy in patients with peptic ulcer bleeding. 2002 Aliment. Pharmacol. Ther. pmid:11856088
Choi IJ et al. Efficacy of low-dose clarithromycin triple therapy and tinidazole-containing triple therapy for Helicobacter pylori eradication. 2002 Aliment. Pharmacol. Ther. pmid:11856089
Bazzoli F et al. Low-dose lansoprazole and clarithromycin plus metronidazole vs. full-dose lansoprazole and clarithromycin plus amoxicillin for eradication of Helicobacter pylori infection. 2002 Aliment. Pharmacol. Ther. pmid:11856090
Malfertheiner P et al. Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report. 2002 Aliment. Pharmacol. Ther. pmid:11860399
Calvet X et al. Two-week dual vs. one-week triple therapy for cure of Helicobacter pylori infection in primary care: a multicentre, randomized trial. 1999 Aliment. Pharmacol. Ther. pmid:10383508
Sieg A et al. Short-term triple therapy with lansoprazole 30 mg or 60 mg, amoxycillin and clarithromycin to eradicate Helicobacter pylori. 1999 Aliment. Pharmacol. Ther. pmid:10383519
Cestari R Ranitidine bismuth citrate (RBC) based triple therapy for 7 days is more effective than RBC plus clarithromycin for 14 days in dyspeptic patients with Helicobacter pylori infection. H. Pylori Lombardy Group. 1998 Aliment. Pharmacol. Ther. pmid:9798804
Grimley CE et al. Comparison of two 3-day Helicobacter pylori eradication regimens with a standard 1-week regimen. 1999 Aliment. Pharmacol. Ther. pmid:10383520
Spadaccini A et al. Triple regimens using lansoprazole or ranitidine bismuth citrate for Helicobacter pylori eradication. 1998 Aliment. Pharmacol. Ther. pmid:9798805
Houben MH et al. Randomized trial of omeprazole and clarithromycin combined with either metronidazole or amoxycillin in patients with metronidazole-resistant or -susceptible Helicobacter pylori strains. 1999 Aliment. Pharmacol. Ther. pmid:10383522
Bortolotti M et al. Effects of oral clarithromycin and amoxycillin on interdigestive gastrointestinal motility of patients with functional dyspepsia and Helicobacter pylori gastritis. 1998 Aliment. Pharmacol. Ther. pmid:9798808
Iijima K et al. Long-term effect of Helicobacter pylori eradication on the reversibility of acid secretion in profound hypochlorhydria. 2004 Aliment. Pharmacol. Ther. pmid:15153171
Veldhuyzen Van Zanten S et al. One-week triple therapy with esomeprazole provides effective eradication of Helicobacter pylori in duodenal ulcer disease. 2000 Aliment. Pharmacol. Ther. pmid:11121908
Spadaccini A et al. Omeprazole versus ranitidine: short-term triple-therapy in patients with Helicobacter pylori-positive duodenal ulcers. 1996 Aliment. Pharmacol. Ther. pmid:8899094
Perri F et al. Randomized study of different 'second-line' therapies for Helicobacter pylori infection after failure of the standard 'Maastricht triple therapy'. 2003 Aliment. Pharmacol. Ther. pmid:14535875
Mason JM et al. Helicobacter pylori eradication in long-term proton pump inhibitor users is highly cost-effective: economic analysis of the HELPUP trial. 2008 Aliment. Pharmacol. Ther. pmid:18793340
Fraser AG Editorial: replacing standard proton pump inhibitors with vonoprazan may breathe new life into triple therapy for Helicobacter pylori. 2017 Aliment. Pharmacol. Ther. pmid:28776748
Williams MP et al. Seven-day treatment for Helicobacter pylori infection: ranitidine bismuth citrate plus clarithromycin and tetracycline hydrochloride. 1997 Aliment. Pharmacol. Ther. pmid:9305479
Janssen MJ et al. A systematic comparison of triple therapies for treatment of Helicobacter pylori infection with proton pump inhibitor/ ranitidine bismuth citrate plus clarithromycin and either amoxicillin or a nitroimidazole. 2001 Aliment. Pharmacol. Ther. pmid:11328254
Tankovic J et al. Impact of Helicobacter pylori resistance to clarithromycin on the efficacy of the omeprazole-amoxicillin-clarithromycin therapy. 2001 Aliment. Pharmacol. Ther. pmid:11328266
Chi CH et al. Quadruple therapy containing amoxicillin and tetracycline is an effective regimen to rescue failed triple therapy by overcoming the antimicrobial resistance of Helicobacter pylori. 2003 Aliment. Pharmacol. Ther. pmid:12895220
Higuchi K et al. Is eradication sufficient to heal gastric ulcers in patients infected with Helicobacter pylori? A randomized, controlled, prospective study. 2003 Aliment. Pharmacol. Ther. pmid:12492739
Coelho LG et al. Once-daily, low-cost, highly effective Helicobacter pylori treatment to family members of gastric cancer patients. 2003 Aliment. Pharmacol. Ther. pmid:12492742
Zullo A et al. Clarithromycin or levofloxacin in the sequential therapy for H. pylori eradication? 2010 Aliment. Pharmacol. Ther. pmid:20518756
Colin R Duodenal ulcer healing with 1-week eradication triple therapy followed, or not, by anti-secretory treatment: a multicentre double-blind placebo-controlled trial. 2002 Aliment. Pharmacol. Ther. pmid:12030959